文献速递眼底病与葡萄膜炎

伏格特-小柳-原田病患者结局:一线抗代谢药作为激素节省治疗葡萄膜炎试验

Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial.
PubMed 文献 · Am J Ophthalmol · 2024-06-22

该研究为随机、观察者设盲、比较有效性试验的子分析,纳入93例伏格特-小柳-原田病(VKH)患者,比较甲氨蝶呤(MTX)与吗替麦考酚酯(MMF)作为激素节省治疗的效果。结果显示两组治疗成功率无显著差异(MTX 80.4% vs MMF 64.1%,P=0.12),但MTX在降低视网膜中央亚区厚度和消退浆液性视网膜脱离方面优于MMF;急性VKH患者视力改善优于慢性患者。

要点

  • MTX与MMF在VKH激素节省治疗成功率上无显著差异(P=0.12)。
  • MTX在降低视网膜中央亚区厚度(P=0.003)和消退浆液性视网膜脱离(P=0.02)方面优于MMF。
  • 急性VKH患者最佳矫正视力改善(P<0.001)和中央亚区厚度降低(P=0.02)均优于慢性患者。

核心结论

  • MTX和MMF作为VKH的激素节省免疫抑制治疗具有可比的结果。
  • 急性VKH较慢性VKH的视力改善更大。

研究设计与样本

  • 研究为一线抗代谢药作为激素节省治疗葡萄膜炎试验(First-line Antimetabolites as Steroid-sparing Treatment Uveitis Trial)中VKH患者的子分析。
  • 试验为随机、观察者设盲、比较有效性试验,按治疗(MTX vs MMF)和疾病分期(急性 vs 慢性)进行比较。
  • 非感染性葡萄膜炎患者接受标准化激素逐渐减量方案,并按1:1区组随机分配至每周口服MTX 25 mg或口服MMF 1.5 g每日两次。
  • 216例入组患者中93例为VKH,49例随机至MTX组、44例至MMF组,其中85例(MTX组46例、MMF组39例)纳入主要结局分析。

主要发现

  • 主要结局6个月时激素节省控制葡萄膜炎的治疗成功率:MTX组80.4% vs MMF组64.1%,差异无统计学意义(P=0.12)。
  • 最佳矫正视力改善在两组间无显著差异(P=0.78)。
  • MTX在降低视网膜中央亚区厚度方面优于MMF(P=0.003)。
  • MTX在消退浆液性视网膜脱离方面优于MMF(P=0.02)。
  • 治疗成功率按疾病分期无显著差异(P=0.25),但急性VKH患者较慢性VKH患者最佳矫正视力改善更大(P<0.001)、中央亚区厚度降低更明显(P=0.02)。

关键数值与推荐

  • 主要结局为6个月时激素节省控制葡萄膜炎的治疗成功。
  • 附加结局包括最佳矫正视力变化、视网膜中央亚区厚度、浆液性视网膜脱离消退。
  • 干预方案:口服MTX 25 mg每周一次 vs 口服MMF 1.5 g每日两次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the effectiveness of methotrexate (MTX) and mycophenolate mofetil (MMF) in achieving corticosteroid-sparing control of uveitis in patients with Vogt-Koyanagi-Harada (VKH) disease. METHODS: A subanalysis of patients with VKH from the First-line Antimetabolites as Steroid-sparing Treatment Uveitis Trial, a randomized, observer-masked, comparative effectiveness trial, with comparisons by treatment (MTX vs MMF) and disease stage (acute vs chronic). Individuals with noninfectious uveitis were placed on a standardized corticosteroid taper and block randomized 1:1 to either 25 mg weekly oral MTX or 1.5 g twice daily oral MMF. The primary outcome was treatment success defined by corticosteroid-sparing control of uveitis at 6 months. Additional outcomes included change in best spectacle-corrected visual acuity (BSCVA), retinal central subfield thickness (CST), and resolution of serous retinal detachment (SRD). RESULTS: Ninety-three out of 216 enrolled patients had VKH; 49 patients were randomized to MTX and 44 to MMF, of which 85 patients (46 on MTX, 39 on MMF) contributed to the primary outcome. There was no significant difference in treatment success by antimetabolite (80.4% for MTX compared to 64.1% for MMF; P = .12) or in BSCVA improvement (P = .78). MTX was superior to MMF in reducing CST (P = .003) and resolving SRD (P = .02). There was no significant difference in treatment success by disease stage (P = .25), but patients with acute VKH had greater improvement in BSCVA (P < .001) and reduction of CST (P = .02) than chronic VKH patients. CONCLUSIONS: MTX and MMF have comparable outcomes as corticosteroid-sparing immunosuppressive therapies for VKH. Visual acuity improvement was greater in acute vs chronic VKH. NOTE: Publication of this article is sponsored by the American Ophthalmological Society TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00182929.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Acharya NR, Rathinam SR, Thundikandy R, et al. Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial. Am J Ophthalmol. 2024. PMID: 38909740. doi:10.1016/j.ajo.2024.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。